Publications Database

Martin A. et al. (2004)

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.

American Journal of Psychiatry

161(6), pp. 1125-1127

Read Abstract (New Window) Read Full (New Window)

McCracken J. T. et al. (2014)

Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.

Pharmacogenomics

14(3), pp. 295-302.

Read Abstract (New Window) Read Full (New Window)

McCracken J. T. et al. (2002)

Risperidone in children with autism and serious behavioral problems.

New England Journal of Medicine

347(5), pp. 314-321

Read Abstract (New Window) Read Full (New Window)

McCracken J. T. (2005)

Safety issues with drug therapies for autism spectrum disorders.

Journal of Clinical Psychiatry

66 pp. 32-37

Read Abstract (New Window)

McDougle C. J. et al. (2000)

Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.

Child and Adolescent Psychiatric Clinics of North America

January, 9(1), pp. 201-224.

Read Abstract (New Window)

McDougle C. J. et al. (2005)

Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology.

American Journal of Psychiatry

162(6), pp. 1142-1148

Read Abstract (New Window) Read Full (New Window)

Nikolov R. N. et al. (2009)

Gastrointestinal symptoms in a sample of children with pervasive developmental disorders.

Journal of Autism and Developmental Disorders

39(3), pp. 405-413

Read Abstract (New Window)

Oberman L. M. et al. (2016)

Transcranial magnetic stimulation in autism spectrum disorder: Challenges, promise, and roadmap for future research.

Autism Research

February, 9(2), pp.184-203.

Read Abstract (New Window)

Posey D. J. et al. (2007)

Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.

Biological Psychiatry

61(4), pp. 538-544.

Read Full (New Window)

Scahill L. et al. (2006)

A prospective open trial of guanfacine in children with pervasive developmental disorders.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 589-598.

Read Abstract (New Window) Read Full (New Window)

Scahill L. et al. (2001)

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism.

Journal of Child and Adolescent Psychopharmacology

11(4), pp. 377-388

Read Abstract (New Window)

Scahill L. et al. (2001)

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism.

Journal of Child and Adolescent Psychopharmacology

Winter, 11(4), pp, 377-88.

Read Abstract (New Window)

Scahill L. et al. (2017)

Using a patient-centered outcome measure to test methylphenidate versus placebo in children with autism spectrum disorder.

Journal of Child and Adolescent Psychopharmacology

March, 27(2), pp. 125-131.

Read Abstract (New Window) Read Full (New Window)

Scahill L. et al. (2016)

Weight gain and metabolic consequences of risperidone in young children with autism spectrum disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

May, 55(5), pp. 415-423.

Read Abstract (New Window)

Tierney E. et al. (2007)

Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study.

Psychopharmacology (Berl)

March, 191(1), pp. 149-157.

Read Abstract (New Window)

Umbricht D. et al. (2016)

A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder.

Neuropsychopharmacology

Read Abstract (New Window)

Vitiello B. et al. (2005)

Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone.

Journal of Clinical Psychopharmacology

25(6), pp. 565-569

Read Abstract (New Window)

Vo L. C. et al. (2016)

No apparent cardiac conduction effects of acute treatment with risperidone in children with autism spectrum disorder.

Perceptual and Motor Skills

December, 26(10), pp. 900-908

Read Abstract (New Window)

Volkmar F. R. et al. (2014)

Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

53(2), pp. 237-257.

Read Abstract (New Window) Read Full (New Window)

Williams S. K. et al. (2006)

Risperidone and adaptive behavior in children with autism.

Journal of the American Academy of Child and Adolescent Psychiatry

45(4), pp. 431-439

Read Abstract (New Window) Read Full (New Window)